These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 21646519)

  • 1. Preexisting drug-resistance mutations reveal unique barriers to resistance for distinct antivirals.
    Robinson M; Tian Y; Delaney WE; Greenstein AE
    Proc Natl Acad Sci U S A; 2011 Jun; 108(25):10290-5. PubMed ID: 21646519
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of a novel replication-competent hepatitis C virus variant that confers the sofosbuvir resistance.
    Leumi S; Guo M; Lu J; Wang Z; Gan T; Han L; Ngari J; Tong Y; Xiang X; Xie Q; Wang L; Zhong J
    Antiviral Res; 2022 Jan; 197():105224. PubMed ID: 34864126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dehydrojuncusol, a Natural Phenanthrene Compound Extracted from
    Sahuc ME; Sahli R; Rivière C; Pène V; Lavie M; Vandeputte A; Brodin P; Rosenberg AR; Dubuisson J; Ksouri R; Rouillé Y; Sahpaz S; Séron K
    J Virol; 2019 May; 93(10):. PubMed ID: 30842319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutations in HCV non-structural genes do not contribute to resistance to nitazoxanide in replicon-containing cells.
    Yon C; Viswanathan P; Rossignol JF; Korba B
    Antiviral Res; 2011 Sep; 91(3):233-40. PubMed ID: 21703309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative study of the genetic barriers and pathways towards resistance of selective inhibitors of hepatitis C virus replication.
    Delang L; Vliegen I; Froeyen M; Neyts J
    Antimicrob Agents Chemother; 2011 Sep; 55(9):4103-13. PubMed ID: 21709100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro efficacy of approved and experimental antivirals against novel genotype 3 hepatitis C virus subgenomic replicons.
    Yu M; Corsa AC; Xu S; Peng B; Gong R; Lee YJ; Chan K; Mo H; Delaney W; Cheng G
    Antiviral Res; 2013 Nov; 100(2):439-45. PubMed ID: 24013001
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a novel dicistronic reporter-selectable hepatitis C virus replicon suitable for high-throughput inhibitor screening.
    Hao W; Herlihy KJ; Zhang NJ; Fuhrman SA; Doan C; Patick AK; Duggal R
    Antimicrob Agents Chemother; 2007 Jan; 51(1):95-102. PubMed ID: 17060518
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ribavirin resistance in hepatitis C virus replicon-containing cell lines conferred by changes in the cell line or mutations in the replicon RNA.
    Pfeiffer JK; Kirkegaard K
    J Virol; 2005 Feb; 79(4):2346-55. PubMed ID: 15681435
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evolution of resistant M414T mutants among hepatitis C virus replicon cells treated with polymerase inhibitor A-782759.
    Lu L; Mo H; Pilot-Matias TJ; Molla A
    Antimicrob Agents Chemother; 2007 Jun; 51(6):1889-96. PubMed ID: 17371824
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selection and characterization of hepatitis C virus replicons dually resistant to the polymerase and protease inhibitors HCV-796 and boceprevir (SCH 503034).
    Flint M; Mullen S; Deatly AM; Chen W; Miller LZ; Ralston R; Broom C; Emini EA; Howe AY
    Antimicrob Agents Chemother; 2009 Feb; 53(2):401-11. PubMed ID: 18936191
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel hepatitis C virus reporter replicon cell lines enable efficient antiviral screening against genotype 1a.
    Robinson M; Yang H; Sun SC; Peng B; Tian Y; Pagratis N; Greenstein AE; Delaney WE
    Antimicrob Agents Chemother; 2010 Aug; 54(8):3099-106. PubMed ID: 20516274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatitis C virus nucleotide inhibitors PSI-352938 and PSI-353661 exhibit a novel mechanism of resistance requiring multiple mutations within replicon RNA.
    Lam AM; Espiritu C; Bansal S; Micolochick Steuer HM; Zennou V; Otto MJ; Furman PA
    J Virol; 2011 Dec; 85(23):12334-42. PubMed ID: 21957306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generation of a chimeric hepatitis C replicon encoding a genotype-6a NS3 protease and assessment of boceprevir (SCH503034) sensitivity and drug-associated mutations.
    Aloia AL; Eyre NS; Black S; Bent SJ; Gaeguta A; Guo Z; Narayana SK; Chase R; Locarnini S; Carr JM; Howe JA; Beard MR
    Antivir Ther; 2015; 20(3):271-80. PubMed ID: 25222708
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro anti-hepatitis C virus (HCV) resistance selection and characterization.
    Mo H
    Curr Protoc Pharmacol; 2011 Jun; Chapter 13():Unit 13B.5. PubMed ID: 21935899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selection of clinically relevant protease inhibitor-resistant viruses using the genotype 2a hepatitis C virus infection system.
    Cheng G; Chan K; Yang H; Corsa A; Pokrovskii M; Paulson M; Bahador G; Zhong W; Delaney W
    Antimicrob Agents Chemother; 2011 May; 55(5):2197-205. PubMed ID: 21357305
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro selection and characterization of HCV replicons resistant to multiple non-nucleoside polymerase inhibitors.
    Delang L; Vliegen I; Leyssen P; Neyts J
    J Hepatol; 2012 Jan; 56(1):41-8. PubMed ID: 21703175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical characterization of the antiviral activity of SCH 900518 (narlaprevir), a novel mechanism-based inhibitor of hepatitis C virus NS3 protease.
    Tong X; Arasappan A; Bennett F; Chase R; Feld B; Guo Z; Hart A; Madison V; Malcolm B; Pichardo J; Prongay A; Ralston R; Skelton A; Xia E; Zhang R; Njoroge FG
    Antimicrob Agents Chemother; 2010 Jun; 54(6):2365-70. PubMed ID: 20308381
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tracking the evolution of multiple in vitro hepatitis C virus replicon variants under protease inhibitor selection pressure by 454 deep sequencing.
    Verbinnen T; Van Marck H; Vandenbroucke I; Vijgen L; Claes M; Lin TI; Simmen K; Neyts J; Fanning G; Lenz O
    J Virol; 2010 Nov; 84(21):11124-33. PubMed ID: 20739521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of Preexisting Hepatitis C Virus Genotype 6 NS3, NS5A, and NS5B Polymorphisms on the
    McPhee F; Ueland J; Vellucci V; Bowden S; Sievert W; Zhou N
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30718256
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical Characterization and In Vivo Efficacy of GSK8853, a Small-Molecule Inhibitor of the Hepatitis C Virus NS4B Protein.
    Pouliot JJ; Thomson M; Xie M; Horton J; Johnson J; Krull D; Mathis A; Morikawa Y; Parks D; Peterson R; Shimada T; Thomas E; Vamathevan J; Van Horn S; Xiong Z; Hamatake R; Peat AJ
    Antimicrob Agents Chemother; 2015 Oct; 59(10):6539-50. PubMed ID: 26259798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.